Gérald Massonnet

Data from Evaluating Patient-Derived Colorectal Cancer Xenografts as Preclinical Models by Comparison with Patient Clinical Data

Manoel Nunes, Patricia Vrignaud, Sophie Vacher, Sophie Richon et autres

Abstract Development of targeted therapeutics required translationally relevant preclinical models with well-characterized cancer genome alterations. Here, by studying 52 colorectal patient-derived tumor xenografts (PDX), we examined key molecular alterations of the IGF2–PI3K and ERBB–RAS pathways and response to cetuximab. PDX molecular data …

Supplementary Table 1 from Evaluating Patient-Derived Colorectal Cancer Xenografts as Preclinical Models by Comparison with Patient Clinical Data

Manoel Nunes, Patricia Vrignaud, Sophie Vacher, Sophie Richon et autres

Genomic alterations in KRAS/BRAF/NRA S wild-type xenografts, according to their response to cetuximab. Tumors were considered to be amplified if the gene copy number was >3. Gene overexpression is defined by an expression superior to average in all PDX panel + 1 …

Supplementary Figure 1 from Evaluating Patient-Derived Colorectal Cancer Xenografts as Preclinical Models by Comparison with Patient Clinical Data

Manoel Nunes, Patricia Vrignaud, Sophie Vacher, Sophie Richon et autres

Genomic alterations of IGF2-PI3K pathway in MSS human colorectal cancer cell lines. A. Gene expression, gene copy number and mutation data provided by the Cancer Cell Line Encyclopedia were studied in the 36 MSS cell lines out of the cohort of the …

Supplementary Figure 2 from Evaluating Patient-Derived Colorectal Cancer Xenografts as Preclinical Models by Comparison with Patient Clinical Data

Manoel Nunes, Patricia Vrignaud, Sophie Vacher, Sophie Richon et autres

Example of 2 PDXs treated with cetuximab (one red arrow for each injection).

Supplementary Figure 2 from Evaluating Patient-Derived Colorectal Cancer Xenografts as Preclinical Models by Comparison with Patient Clinical Data

Manoel Nunes, Patricia Vrignaud, Sophie Vacher, Sophie Richon et autres

Example of 2 PDXs treated with cetuximab (one red arrow for each injection).

Supplementary Figure 1 from Evaluating Patient-Derived Colorectal Cancer Xenografts as Preclinical Models by Comparison with Patient Clinical Data

Manoel Nunes, Patricia Vrignaud, Sophie Vacher, Sophie Richon et autres

Genomic alterations of IGF2-PI3K pathway in MSS human colorectal cancer cell lines. A. Gene expression, gene copy number and mutation data provided by the Cancer Cell Line Encyclopedia were studied in the 36 MSS cell lines out of the cohort of the …

Supplementary Table 1 from Evaluating Patient-Derived Colorectal Cancer Xenografts as Preclinical Models by Comparison with Patient Clinical Data

Manoel Nunes, Patricia Vrignaud, Sophie Vacher, Sophie Richon et autres

Genomic alterations in KRAS/BRAF/NRA S wild-type xenografts, according to their response to cetuximab. Tumors were considered to be amplified if the gene copy number was >3. Gene overexpression is defined by an expression superior to average in all PDX panel + 1 …

Data from Evaluating Patient-Derived Colorectal Cancer Xenografts as Preclinical Models by Comparison with Patient Clinical Data

Manoel Nunes, Patricia Vrignaud, Sophie Vacher, Sophie Richon et autres

Abstract Development of targeted therapeutics required translationally relevant preclinical models with well-characterized cancer genome alterations. Here, by studying 52 colorectal patient-derived tumor xenografts (PDX), we examined key molecular alterations of the IGF2–PI3K and ERBB–RAS pathways and response to cetuximab. PDX molecular data …

Abstract 5782: Selumetinib-based therapy in uveal melanoma patient-derived xenografts

Didier Decaudin, Rania El Botty, Béré Diallo, Gérald Massonnet et autres

Abstract Purpose: The prognosis of metastatic uveal melanoma (UM) patients remains one of the worst observed in human cancers. The identification of frequently mutated GNAQ/GNA11 and the activation of MAPK signaling in UM raise the possibility of using efficient targeted therapies such …

fr, gb (code pays fourni par la source)

Selumetinib-based therapy in uveal melanoma patient-derived xenografts

Didier Decaudin, Rania El Botty, Béré Diallo, Gérald Massonnet et autres

// Didier Decaudin 1, 2 , Rania El Botty 1 , Béré Diallo 1 , Gerald Massonnet 1 , Justine Fleury 1 , Adnan Naguez 1 , Chloé Raymondie 1 , Emma Davies 3 , Aaron Smith 3 , Joanne Wilson 3 …

fr, gb (code pays fourni par la source)

The humanized anti-human AMHRII mAb 3C23K exerts an anti-tumor activity against human ovarian cancer through tumor-associated macrophages

Houcine Bougherara, Fariba Némati, Nicolás André, Gérald Massonnet et autres

// Houcine Bougherara 1, 2, 3, * , Fariba Némati 4, * , André Nicolas 5 , Gérald Massonnet 4 , Martine Pugnière 6 , Charlotte Ngô 7 , Marie-Aude Le Frère-Belda 8 , Alexandra Leary 9 , Jérôme Alexandre 1, 3, …

fr (code pays fourni par la source)

Nanobodies against surface biomarkers enable the analysis of tumor genetic heterogeneity in uveal melanoma patient‐derived xenografts

Ronan Crépin, David Gentien, A Duché, Audrey Rapinat et autres

Monoclonal antibodies specific for biomarkers expressed on the surface of uveal melanoma (UM) cells would simplify the immune capture and genomic characterization of heterogeneous tumor cells originated from patient-derived xenografts (PDXs). Antibodies against four independent tumor antigens were isolated by panning a …

fr, si (code pays fourni par la source)